GlobeNewswire Inc.··NaRegeneron Bets $125M on Parabilis Partnership to Unlock 'Undruggable' Cancer Targets
Regeneron invests $125M upfront with Parabilis to develop novel antibody conjugates targeting previously untreatable intracellular proteins, with $2.2B in potential milestones.
REGNAntibody-Drug Conjugatestherapeutic development